Clinical Trials Browser

High Grade Serous Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Solid Tumors

Prostatic Neoplasms

Breast Neoplasms

Glioblastoma

Ovarian Neoplasms

Triple Negative Breast Neoplasms

Osteosarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

Fallopian Tube Neoplasms, Ovarian Neoplasms

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Ovarian Neoplasm Epithelial

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Uveal Melanoma

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

Triple Negative Breast Neoplasms

Stomach Neoplasms

Non-small-cell Lung Cancer Patients

Squamous Cell Carcinoma of Head and Neck

Prostatic Neoplasms

Castration-Resistant Prostate Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Glioma, Recurrence

Endometrial Carcinosarcoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Biochemically Recurrent Prostate Carcinoma

Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency

Neoplasm Metastasis

Stomach Neoplasms

Prostatic Neoplasms

SCLC,Extensive Stage

Triple Negative Breast Neoplasms

Small Cell Lung Carcinoma

Clinical Trials

CAPRI

RADIOLA

I-SPY

DAPA-ARMOR

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Surgical Pembro +/- Olaparib w TMZ for rGBM

DOVACC

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Olaparib With Ceralasertib in Recurrent Osteosarcoma

ATARI

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

FAB

TAPUR

PETREMAC

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Pembro With Radiation With or Without Olaparib

Pembrolizumab Plus Olaparib in LA-HNSCC

NePtune

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Olaparib In Metastatic Breast Cancer

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

NeoADAPT

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

OLAGLI

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

PHOENIX

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

MOST plus

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

337

THOR

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

GUIDANCE